CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0871 (clinicaltrials.gov NCT No: NCT00899431)
Title:Nonmyeloablative Stem Cell Transplantation with or without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294)
Principal Investigator:Issa F. Khouri
Treatment Agent:Bendamustine HCl; Fludarabine; Lenalidomide; Rituximab; Thymoglobulin
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if lenalidomide, when
given with a stem cell transplant and chemotherapy (bendamustine, fludarabine,
and rituximab), can help to control CLL. The safety of this treatment
combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Bendamustine HCl
Fludarabine
Lenalidomide
Rituximab
Thymoglobulin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Length of stay in the hospital: 3-4 weeks.
Frequency of hospitalization: 2 times over the first year.
Supported By:Celgene Corporation
Return Visit:Every 3 months for the first 18 months. Then every 6 months for 3 years.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Issa F. Khouri
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults